Oncorheumatology is the meeting point of tumour formation and rheumatic diseases. Multiple interactions exist between these two medical specialties. One major field is the topic of malignancies associated with rheumatic diseases, while the other topic covers the development of musculoskeletal disease in cancer patients. In the first group, secondary malignancies associated with rheumatic diseases, role of tumour-associated antigens in rheumatology, the possible carcinogenicity of conventional and targeted antirheumatic drugs and physical therapy of rheumatic patients with recent or current cancer will be discussed. The second large topic includes paraneoplastic syndromes, autoimmune-rheumatic side effects of oncotherapies (chemotherapy and immunotherapy), effects of hormone-deprivation therapies on bone and primary and secondary malignancies of the musculoskeletal system. Orv Hetil. 2020; 161(28): 1151-1165.
Keywords: carcinogenicity; carcinogenitas; célzott terápia; daganatok; immuncheckpointgátlók; immune-checkpoint inhibition; mozgásszervi betegségek; musculoskeletal diseases; oncorheumatology; onkoreumatológia; sarcomas; sarcomák; secondary tumour development; szekunder daganatképződés; targeted therapy; tumours.